Marina Sragovicz

Title: Inventor Spotlight: Marina Sragovicz and Her Neuroprotective Innovations

Introduction

Marina Sragovicz, an accomplished inventor based in San Diego, CA, has made significant contributions to the field of neuroprotective drug development. With one patent to her name, her innovative work revolves around poly-guanidino compounds that play a crucial role in protecting neurons during ischemic or hypoxic crises.

Latest Patents

Sragovicz's patent, titled "Neuroprotective poly-guanidino compounds which block presynaptic N," focuses on the design of neuroprotective drugs that feature at least three branches extending outwardly from a central atom or group. Each branch terminates with a guanidino group. These branches are symmetrically distributed around the central element, which may be a nitrogen atom or a carbon atom, among other structures.

The invention emphasizes the use of starting reagents that incorporate reactive groups at the ends of spacer chains, enabling the production of drugs capable of penetrating the blood-brain barrier. This innovative approach allows the drugs to suppress calcium entry into central nervous system neurons, thereby mitigating excitotoxic damage and addressing excessive neuronal activation, including neuropathic pain.

Career Highlights

Marina Sragovicz's professional journey led her to become a pivotal figure at Cypros Pharmaceutical Corp., where she channels her expertise into the advancement of neuroprotective therapies. Her dedication to research and innovation has positioned her at the forefront of pharmacological developments aimed at addressing critical neural health issues.

Collaborations

Throughout her career, Sragovicz has collaborated with esteemed colleagues such as Paul J. Marangos and Brian W. Sullivan. These partnerships reflect her commitment to fostering a collaborative research environment that enhances the development of groundbreaking solutions in the realm of neuroscience.

Conclusion

Marina Sragovicz's contributions to neuroprotective drug development underscore the importance of innovative research in addressing neurological crises. Her patent for neuroprotective poly-guanidino compounds exemplifies the intersection of creativity and scientific inquiry. As she continues her work at Cypros Pharmaceutical Corp., her innovations have the potential to significantly impact the treatment of severe medical conditions related to neuronal health.